• Jane Whelan, Stefania Bambini, Alessia Biolchi, Brunella Brunelli, and Mirna Robert-Du Ry van Beest Holle.
• Novartis Pharma BV, Hullenbergweg 83-85, 1100 DM Amsterdam, The Netherlands.
• Expert Rev Vaccines. 2015 May 1; 14 (5): 713-36.

AbstractStrains of Neisseria meningitidis serogroup B (MenB) causing invasive meningococcal disease are genetically diverse; however, only a small number of hyperinvasive lineages (CC32, CC41/44, CC269 and CC162) have dominated during the global spread over the past 50 years. Since the mid-1970s, major outbreaks and hyperendemic disease have been reported in Norway, Cuba, France, Canada, New Zealand (and elsewhere), most recently in the USA. We characterized the epidemiology of these MenB outbreaks and their associated clonal complexes and retrospectively assessed the potential coverage offered by the 4CMenB vaccine, a four-component vaccine developed to help confer protection against a broad range of meningococcal B strains causing disease. Of 21 isolates from four clonal complexes evaluated using both human Serum Bactericidal Assay and the Meningococcal Antigen Testing System, coverage ranged from 67 to 100%. 4CMenB shows good potential as a candidate vaccine to be used in the control of new MenB outbreaks globally.

32 keywords...

hide…